Hafez Sherif, Abdelsaid Mohammed, El-Shafey Sally, Johnson Maribeth H, Fagan Susan C, Ergul Adviye
From the Charlie Norwood VA Medical Center (S.H., S.C.F., A.E.), Departments of Physiology (S.H., M.A., S.E.-S., A.E.), Biostatistics (M.H.J.), and Neurology (S.C.F.), Medical College of Georgia, Augusta University; and Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, Augusta (S.H., S.C.F., A.E.).
Stroke. 2016 Mar;47(3):843-51. doi: 10.1161/STROKEAHA.115.011258. Epub 2016 Feb 2.
Acute hyperglycemia worsens the clinical outcomes and exacerbates cerebral hemorrhage after stroke. The mediators of hemorrhagic transformation (HT) in hyperglycemic stroke are not fully understood. Matrix metalloproteinase 3 (MMP3) plays a critical role in the tissue-type plasminogen activator-induced HT. However, the role of MMP3 in exacerbating the HT and worsening the functional outcomes in hyperglycemic stroke remains unknown.
Control/normoglycemic and hyperglycemic (blood glucose, 140-200 mg/dL) male Wistar rats were subjected to middle cerebral artery occlusion for 90 minutes and either 24 hours or 7 days reperfusion. MMP3 was inhibited pharmacologically (UK 356618, 15 mg/kg IV at reperfusion) or knocked down in the brain by shRNA lentiviral particles (injected intracerebroventricular). Neurovascular injury was assessed at 24 hours, and functional outcomes were assessed at 24 hours, day 3, and day 7. MMP3 activity was measured in brain homogenate and cerebral macrovessels. Localization of MMP3 within the neurovascular unit after hyperglycemic stroke was demonstrated by immunohistochemistry.
Hyperglycemia significantly increased MMP3 activity in the brain after stroke, and this was associated with exacerbated HT and worsened functional outcomes. MMP3 inhibition significantly reduced HT and improved functional outcomes.
MMP3 plays a critical role in mediating cerebrovascular injury in hyperglycemic stroke. Our findings point out MMP3 as a potential therapeutic target in hyperglycemic stroke.
急性高血糖会使临床结局恶化,并加重卒中后的脑出血。高血糖性卒中中出血转化(HT)的介导因素尚未完全明确。基质金属蛋白酶3(MMP3)在组织型纤溶酶原激活剂诱导的HT中起关键作用。然而,MMP3在加重高血糖性卒中的HT及使功能结局恶化方面的作用仍不清楚。
将对照/正常血糖和高血糖(血糖140 - 200 mg/dL)的雄性Wistar大鼠进行大脑中动脉闭塞90分钟,再灌注24小时或7天。采用药物抑制MMP3(UK 356618,再灌注时静脉注射15 mg/kg)或通过短发夹RNA慢病毒颗粒(脑室内注射)在脑中敲低MMP3。在24小时评估神经血管损伤,在24小时、第3天和第7天评估功能结局。测量脑匀浆和脑大血管中的MMP3活性。通过免疫组织化学显示高血糖性卒中后MMP3在神经血管单元内的定位。
高血糖显著增加卒中后脑内MMP3活性,这与HT加重和功能结局恶化相关。抑制MMP3可显著减少HT并改善功能结局。
MMP3在介导高血糖性卒中的脑血管损伤中起关键作用。我们的研究结果指出MMP3是高血糖性卒中的一个潜在治疗靶点。